At the beginning of 2022, the share price continued to decline, and the leading medical device company Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) threw another large repurchase plan of RMB 1 billion on January 13
source: company announcement
This is the second large-scale repurchase implemented by Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) in nearly half a year. The last repurchase amount was also 1 billion yuan.
Li Xiting, chairman of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) said that the implementation of repurchase is because he is firmly optimistic about the future development of the company and continues to be optimistic about the long-term value of the company. For the news that some time ago, the sales staff of the online transmission company resigned, the performance did not meet expectations, and the inspection production line of Shanghai branch could not complete the task, Li Xiting responded to the China Securities Journal Taurus reporter on January 13, saying: “it is sheer nonsense.”
buy back with another 1 billion yuan
On January 13, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) issued an announcement on share repurchase. The announcement said that it plans to use its own funds to repurchase part of the company’s public shares in the form of centralized bidding transactions, with a total repurchase amount of 1 billion yuan.
The announcement shows that the repurchase price does not exceed 400.00 yuan / share. Based on 400 yuan / share, it is estimated that the number of repurchases will be 2.5 million shares, accounting for 0.2056% of the current total share capital of the company. The repurchase period shall not exceed 12 months from the date when the board of directors deliberates and approves the share repurchase plan.
For the reasons for repurchase, the announcement shows that it is based on the recognition of the company’s future development prospects and internal value, so as to safeguard the interests of investors and enhance investor confidence.
Since the beginning of 2022, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) share price has experienced a wave of obvious correction. As of the closing on January 13, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) closed at 323.49 yuan / share, corresponding to a market value of nearly 400 billion yuan, down more than 15% in the past nine trading days.
This repurchase is the second repurchase initiated by Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) in the past six months. On August 26, 2021, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) offered a repurchase plan of RMB 1 billion for the first time. Only one week later, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) announced that it had completed the repurchase plan in full.
chairman of the company: firmly optimistic about future development
After the disclosure of the repurchase announcement, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) chairman Li Xiting was interviewed by the China Securities Journal · China Securities Taurus reporter for the first time.
Li Xiting also responded to a series of market rumors, such as the resignation of the online Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) salesperson some time ago, the performance did not meet expectations, and the inspection production line of Shanghai branch could not complete the task.
He said: “this news is sheer nonsense. In 2021, Mindray’s overall operating performance is good and its personnel are stable.”
For the expectation of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) business development in 2022, Li Xiting believes that there are four important directions worthy of attention:
First of all, IVD business growth accelerated, the promotion of new products in the four pillars of blood cell, biochemistry, luminescence and coagulation accelerated, the installation target improved, the international breakthrough of reagent business, and the reagent sales gradually increased.
Secondly, the company will continue to support new medical infrastructure around the world. With excellent product performance, perfect multi product solutions and SanRui IT solutions, the company will seize good growth opportunities, continue to achieve breakthroughs and penetration of high-end hospitals, and expand brand influence.
Third, some orthopedic and IVD products benefited from the impact of centralized procurement, DRGs and other policies in some regions to accelerate the improvement of market coverage and share.
Fourth, emerging businesses with high potential, such as animal medicine, minimally invasive surgery, AED and orthopedics, will also increase R & D investment, accelerate the listing of new products and continue to achieve rapid growth.
